NYSE:AORTMedical Equipment
Assessing Artivion (AORT) Valuation After FDA Approval Of NEXUS Aortic Arch System
Artivion (AORT) is back in focus after the FDA approved the NEXUS Aortic Arch System, a minimally invasive device for aortic arch disease that also activates the company’s option to acquire developer Endospan.
See our latest analysis for Artivion.
The FDA approval appears to have revived interest in Artivion, with a 7 day share price return of 15.31% and a 1 day move of 2.50% lifting the stock to $38.57. However, the 1 year total shareholder return of 66.75% contrasts with weaker year to date...